Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.

Félix Blanc-Durand Roseline Tang Margaux Pommier Marzieh Nashvi Sophie Cotteret Catherine Genestie Audrey Le Formal Patricia Pautier Judith Michels Maria Kfoury Robert Hervé Sylvie Mengue Estelle Wafo Antoine Elies Gregoire Miailhe Jennifer Uzan Etienne Rouleau Alexandra Leary

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

OC patients with high levels of BRCA1 hypermethylation are very likely to have high GIS and therefore represent good candidates for PARPi treatment. These results may be relevant to other tumor types for HRD prediction.

Keyphrases

dna methylation
ejection fraction
end stage renal disease
newly diagnosed
transcription factor
gene expression
prognostic factors
breast cancer risk
replacement therapy
patient reported